NanoViricides Completes NV-387 Oral Gummies Manufacturing, Prepares for Phase II Monkeypox Trial

NanoViricides, Inc. announced that it will present at NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company's broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.

The completion of NV-387 Oral Gummies manufacturing represents a significant milestone for the clinical stage company that is creating special purpose nanomaterials for antiviral therapy. This development is particularly important because NV-387 is a unique broad-spectrum antiviral that has shown effectiveness in animal models for Monkeypox, Smallpox, and Measles, in addition to its planned development as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. The company's progress can be followed through its newsroom at https://ibn.fm/NNVC.

The advancement toward Phase II human clinical trials for monkeypox treatment comes at a critical time when antiviral therapies remain limited for this disease. The Democratic Republic of Congo has experienced significant monkeypox outbreaks in recent years, making the potential development of an effective oral treatment particularly relevant for global health. The successful completion of Phase I human clinical trials in healthy volunteers with no reported adverse events provides a solid safety foundation for further development.

NanoViricides' presentation at the investment conference will likely focus on the broader implications of its antiviral platform technology. The company's approach represents a novel strategy in antiviral drug development, potentially offering treatments for multiple viral diseases through a single platform. This could have significant implications for pandemic preparedness and response capabilities worldwide. The company's other advanced drug candidate, NV-HHV-1 for the treatment of all Herpesvirus infections including HSV-1, HSV-2, VZV Shingles and Chickenpox, further demonstrates the platform's versatility.

The manufacturing completion and upcoming clinical trial preparations position NanoViricides at an important inflection point in its development trajectory. As the company moves toward Phase II trials, the medical community will be watching closely for efficacy data that could validate the broad-spectrum approach to antiviral therapy. The oral gummies formulation represents an important advancement in drug delivery that could improve patient compliance and accessibility, particularly in resource-limited settings like the Democratic Republic of Congo where the Phase II trial is planned.